


# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3 **1 Development of an enzyme-linked immunosorbent (ELISA)**  
4 **2 for natamycin residues in foods based on a specific**  
5 **3 monoclonal antibody**  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

5 Yanni Chen, Dezhao Kong, Liqiang Liu, Shanshan Song, Hua Kuang, Chuanlai Xu\*

6  
7 An indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) was  
8 developed based on a sensitive and specific monoclonal antibody (mAb) against  
9 natamycin (Nata) for Nata detection in milk, juice, yoghurt, and cheese samples. The  
10 working range of ic-ELISA was 0.64–4.46  $\mu\text{g L}^{-1}$  with an  $\text{IC}_{50}$  value of 1.69  $\mu\text{g L}^{-1}$ .  
11 The average recoveries of milk, juice, yoghurt, and cheese samples spiked with Nata  
12 were 103–121%, 103–121%, 84–114%, and 89–108%, respectively. The results  
13 indicated that ic-ELISA can be effectively applied for Nata analysis in these food  
14 products.  
15  
16  
17  
18

---

56 *State Key Lab of Food Science and Technology, School of Food Science and Technology,*  
57 *Jiangnan University, Wuxi, Jiangsu, 214122, PRC. E-mail: xcl@jiangnan.edu.cn; Tel: 0510-85329076*

## 1 Introduction

2 Foods are prone to be contaminated by microorganisms, which negatively affect food  
3 quality and consumers acceptance. Preservatives are commonly added to foods to  
4 inhibit microbial growth, ensure safety, and lengthen shelf-life <sup>1</sup>. Natamycin (Nata),  
5 which is extensively used as a food preservative <sup>2-4</sup>, is produced through the  
6 fermentation of streptomycetes. Therefore, Nata is a natural antifungal compounds,  
7 which exhibits broad spectrum activity against yeast and mould by binding to sterols,  
8 specifically ergosterol, to restrain fungal growth <sup>5, 6</sup>. Nata cannot inhibit bacterial  
9 growth, therefore it cannot affect the natural mature process of yogurt <sup>2</sup>, cheese <sup>7</sup>, ham  
10 <sup>8</sup>, or dry sausage <sup>9</sup>. Several countries and organizations have set regulatory levels for  
11 Nata residue in foods. Through Annex III Directive 95/2/EC, European Union states  
12 that Nata can be used as an additive for the surface treatment of semi-hard, semi-soft  
13 cheeses and dry, cured sausages at a maximum level of 1 mg dm<sup>-2</sup> with a depth no  
14 greater than 5 mm <sup>10</sup>. According to the Joint Food and Agriculture Organization/World  
15 Health Organization Expert Committee on Food Additives (JECFA), the acceptable  
16 daily intake (ADI) of Nata should be 0.3 mg kg<sup>-1</sup> body weight <sup>11</sup>. However, an early  
17 clinical study has reported that Nata induces nausea, diarrhea, anorexia and other  
18 symptoms, when used for systemic mycoses. Additionally, the daily ingestion of Nata  
19 can weaken the immune system <sup>11</sup>. As a result, it is necessary to develop effective  
20 methods for the detection of Nata residues in foods.

21 Several analytical methods have been established for Nata analysis in foods,  
22 including high performance liquid chromatography coupled to diode-array detection  
23 (HPLC-DAD) <sup>10</sup>, reserved-phase high performance liquid chromatography (RP-HPLC)  
24 <sup>12</sup>, high-performance liquid chromatography coupled to high resolution mass  
25 spectrometry (HPLC-HRMS) <sup>13</sup>, and ultrahigh-performance liquid chromatography

1  
2  
3 1 coupled to tandem mass spectrometry (UHPLC-TMS)<sup>11</sup>. All these methods are both  
4  
5 2 sensitive and specific; however, they require laborious sample pre-treatments that are  
6  
7 3 time-consuming and costly. Additionally, expensive instruments and highly qualified  
8  
9 4 personnel are required to implement these methods.

5 The enzyme-linked immunosorbent assay (ELISA) is cost-effective, sensitive,  
6  
7 6 selective, and simple for the analysis of various samples including large analytes such  
8  
9 7 as microorganism<sup>14, 15</sup> and proteins<sup>16, 17</sup> and small analytes such as heavy metals<sup>18, 19</sup>,  
10  
11 8 hormones<sup>20, 21</sup>, pesticides<sup>22, 23</sup>, and antibiotics<sup>24-26</sup>. To the best of our knowledge, a  
12  
13 9 mAb -based ELISA for Nata detection in foods has not been developed. This paper  
14  
15 10 aims to produce a specific and sensitive mAb and establish an indirect competitive  
16  
17 11 ELISA (ic-ELISA) for the Nata analysis in foods.  
18  
19 12

## 13 **Materials and methods**

### 14 **Reagents**

15 Natamycin hydrochloride, tylosin tartrate, tilmicpsin, vancomycin hydrochloride,  
16  
17 16 gentamycin sulfate, kanamycin sulfate, streptomycin sulfate, neomycin sulfate,  
18  
19 17 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-Hydroxysuccinimide  
20  
21 18 (NHS), and N, N' -Carbonyldiimidazole (CDI) were purchased from J&K Scientific  
22  
23 19 Ltd. (Beijing, China). Bovine serum albumin (BSA), ovalbumin (OVA), Freund's  
24  
25 20 complete and incomplete adjuvant, 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic  
26  
27 21 acid (HEPES), 25% glutaraldehyde (GA) solution, 3,3',5,5'-tetramethylbenzidine  
28  
29 22 (TMB), and polyethylene glycol 1500 (PEG 1500) were obtained from Sigma-Aldrich  
30  
31 23 (St. Louis, MO, USA). Enzyme immunoassay-grade horseradish peroxidase  
32  
33 24 (HRP)-labelled goat anti-mouse immunoglobulin was supplied by Hua Mei Co.  
34  
35 25 (Shanghai, China). RPMI-1640 cell culture medium, 50× HAT supplement

1 (containing hypoxanthine aminopterin thymidine), 100× HT supplement (containing  
2 hypoxanthine thymidine), and fetal bovine serum were obtained from Gibco BRL  
3 (Paisley, Scotland). All other chemicals and solvents were analytical grade.

## 4 5 **Instruments**

6 Absorbance measurements were fulfilled on a spectrophotometric microtiterplate  
7 reader (Thermo, MA, USA). An ultraviolet-visible spectrophotometer (Agilent, LA,  
8 USA) was used for UV spectra measurements. Centrifugations were implemented by  
9 a high-speed tabletop refrigerated centrifuge (Thermo, MA, USA). Milli-Q water  
10 purification system was purchased from Millipore (Bedford, MA).

## 11 12 **Buffers and Solutions**

13 The buffers and solutions used in this study have been described elsewhere <sup>27</sup>. The  
14 buffers and solutions included (1) coating buffer: 0.05 M carbonate buffer (CB, pH  
15 9.6); (2) blocking buffer: 0.05 M CB with 0.2% gelatin (w/v); (3) washing buffer:  
16 0.01 M PBS (pH 7.2) with 0.05% Tween-20 (v/v) (PBST); (4) assay buffer: 0.01 M  
17 HEPES (pH 7.2) with 5% methanol; (5) antibody diluent: 0.01 M PBS with 0.1%  
18 (w/v) gelatin and 0.05% (v/v) Tween 20; (6) substrate buffer: 100 mL of 0.1 M citrate  
19 phosphate buffer (pH 5.0) containing 18 μL of 30% H<sub>2</sub>O<sub>2</sub>; (7) TMB: 60 mg TMB  
20 dissolved in 100 mL ethylene glycol; (8) TMB substrate solution: 5:1 v/v mixture of  
21 substrate buffer and TMB solution; (9) 2 M H<sub>2</sub>SO<sub>4</sub>.

## 22 23 **Synthesis of Immunogens and Coating Antigens**

24 Due to the unique aliphatic amino group, the immunogens and coating antigens of  
25 Nata were synthesized through GA method, EDC method, and CDI method. Hence,

1  
2  
3 1 there were nine combinations of immunogens and coating antigens (shown in **Table**  
4  
5 2 **1**). For the GA method, 50  $\mu$ L of 25% GA solution was added dropwise into 30 mg of  
6  
7 3 Nata dissolved in 4 mL of methanol. The mixture solution was allowed to react for 20  
8  
9 4 min with stirring at room temperature prevented from light. Subsequently, the mixture  
10  
11 5 was slowly added into 100 mg BSA/OVA dissolved in 5 mL PBS, allowed to react for  
12  
13 6 4 h at room temperature in dark, following with dialysis for 3 d using PBS. For EDC  
14  
15 7 method, 30 mg of Nata dissolved in 4 mL of methanol was activated by adding with  
16  
17 8 13 mg of EDC and 12.6 mg of NHS for 1 h at room temperature kept from light. Then,  
18  
19 9 the mixture was slowly added into 100 mg of BSA/OVA dissolved in 5 mL PBS to  
20  
21 10 react for 8 h at room temperature in dark, following with dialysis for 3 d using PBS.  
22  
23 11 For the CDI method, 30 mg of Nata dissolved in 4 mL of methanol without water was  
24  
25 12 mixed with 6.8 mg of CDI to react for 30 min with at 37°C prevented from light. The  
26  
27 13 solution was added into 100 mg of BSA/OVA dissolved in PBS to form conjugates.  
28  
29 14 The final solution was dialyzed for 3 d. The conjugates ratio was confirmed by  
30  
31 15 UV-vis.  
32  
33  
34  
35  
36  
37  
38  
39

### 17 **Immunization protocol**

40  
41 18 The immunization protocol was referred to standard schedule <sup>28</sup>. Briefly, eighteen  
42  
43 19 BALB/c female mice were randomly divided into three groups; each group was  
44  
45 20 subcutaneously injected at multiple points with one of three different immunogens  
46  
47 21 (Nata-GA-BSA, Nata-EDC-BSA, and Nata-CDI-BSA). The first immunization was  
48  
49 22 performed with 100  $\mu$ g immunogen emulsified with Freund's complete adjuvant. Four  
50  
51 23 weeks after the initial injection, booster immunizations were administered with a half  
52  
53 24 amount of initial injection emulsified with Freund's incomplete adjuvant. After the  
54  
55 25 third immunization, ic-ELISA was implemented to evaluate the titer and IC<sub>50</sub> values  
56  
57  
58  
59  
60

1  
2  
3 of mice sera. The mouse with the highest titer and lowest IC<sub>50</sub> was screened as the  
4  
5 spleen donor for cell fusion. About 20 d prior to cell fusion, a final intra-peritoneal  
6  
7 injection (30 µg immunogens directly dissolved in 100 µL physiological saline) was  
8  
9 implemented.  
10  
11

## 12 13 14 **Cell Fusion and hybridoma screening**

15  
16 Cell fusion and hybridoma screening were performed according to standard protocol  
17  
18 <sup>29</sup>. Briefly, spleen was rapidly removed from mouse and carefully ground to yield  
19  
20 splenocytes, which were fused with mouse Sp2/0 myeloma cells under the effect of  
21  
22 PEG 1500. The hybridoma cells were distributed into 96-well plates, cultivated by  
23  
24 HAT medium containing 20% bovine fetal serum, and incubated for 7 d at 37°C and 5%  
25  
26 CO<sub>2</sub>. The supernatants were evaluated by ic-ELISA to screen the best cell line with  
27  
28 the highest titer and the lowest IC<sub>50</sub> values, which was used to generate sub-clones  
29  
30 that were intraperitoneally administered to mice primed with paraffin. The ascites  
31  
32 were purified by saturated-ammonium-sulfate method to obtain pure mAb. The  
33  
34 concentrations of antibodies were evaluated by UV-vis spectroscopy at 278 nm. The  
35  
36 antibodies were labeled and stored at -20°C for future use.  
37  
38  
39  
40  
41  
42

## 43 **ic-ELISA**

44  
45 Bi-dimensional titration assays were performed to determine the most appropriate  
46  
47 antibody concentration and the suitable coating antigen concentration for ic-ELISA <sup>30</sup>.  
48  
49 Briefly, 100 µL of Nata-OVA (diluted with coating buffer to the concentrations of 1,  
50  
51 0.5, 0.25, 0.125, and 0.0625 µg L<sup>-1</sup>) was coated on the microtiter plates at 37°C for 2  
52  
53 h. Then the microtiter plates were subsequently washed three times with PBST and  
54  
55 added with 200 µL of blocking buffer at 37°C for 2 h. 50 µL of assay buffer and 50  
56  
57  
58  
59  
60

1  
2  
3 1  $\mu\text{L}$  of mAb (diluted with antibody diluent in 1:4000, 1:8000, 1:16000, 1:32000,  
4  
5 2 1:64000, and 1:128000) were added into each well and incubated for 30 min at 37°C.  
6  
7 3 The antigen-antibody reaction was terminated by washing the microtiter plates three  
8  
9 4 times with PBST, which followed by adding into each well with 100  $\mu\text{L}$  of  
10  
11 5 peroxidase-labelled goat anti-mouse IgG (diluted 3,000 times with antibody diluent)  
12  
13 6 and incubating for 30 min at 37°C. The microtiter plates were washed for four times  
14  
15 7 with PBST to remove the excess peroxidase-labelled goat anti-mouse IgG. 100  $\mu\text{L}$  of  
16  
17 8 TMB substrate solution was added into the plates. Finally, the enzymatic reaction was  
18  
19 9 stopped with 50  $\mu\text{L}$  of 2 M  $\text{H}_2\text{SO}_4$  following with a 15-min incubation at 37°C.  
20  
21 10 Optical density (OD) was measured at 450 nm on the microplate reader, and the  
22  
23 11 results were plotted against the logarithm of analyte concentrations. As a result, the  
24  
25 12 best combination of coating antigen concentration and antibody concentration were  
26  
27 13 determined. The operation procedure of ic-ELISA was carried out according to  
28  
29 14 standard schedule<sup>31</sup>. Briefly, the coating and blocking procedure were similar to the  
30  
31 15 bi-dimensional titration assay. The difference was 50  $\mu\text{L}$  of Nata (diluted with assay  
32  
33 16 buffer to the concentrations of 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20  $\mu\text{g L}^{-1}$ ) and 50  
34  
35 17  $\mu\text{L}$  of mAb (diluted into the optimal concentration) were added into each well and  
36  
37 18 incubated for 30 min at 37°C. The rest of steps were also similar to the bi-dimensional  
38  
39 19 titration assay.  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 21 **Sensitivity**

22  $\text{IC}_{50}$  was defined as the concentration of competing compound that produced a 50%  
23 inhibition of antibody binding to the coating antigen. Generally, it was regarded to be  
24 an indicator of mAb sensitivity. The limit of detection (LOD) was defined as the  
25 lowest concentration<sup>32</sup> that exhibits a signal of 15% inhibition<sup>32</sup>. The detection range of



1  
2  
3 1 ic-ELISA was considered to be the concentration that resulted in 20–80% inhibition  
4  
5 2 <sup>30</sup>.

6  
7  
8  
9  
10 4 **Specificity**

11 The ability of structurally related analogues to combine with the mAb was defined as  
12 specificity. Generally, specificity was assessed by measuring cross-reactivity (CR),  
13  
14 specificity. Generally, specificity was assessed by measuring cross-reactivity (CR),  
15  
16 which was calculated according to the following equation <sup>33</sup>,

17  
18  
19 
$$\text{CR}\% = (\text{IC}_{50} \text{ value of Nata}) / (\text{IC}_{50} \text{ value of related compound}) \times 100.$$

20  
21 The related analogues used to evaluate the specificity are included tylosin and  
22  
23 tilmicosin, which are macrolide antibiotics; vancomycin, which is a glycopeptide  
24  
25 antibiotics; gentamycin, kanamycin, streptomycin, and neomycin, which are  
26  
27 aminoglycosides antibiotics. Among these analogues, tylosin, vancomycin, and four  
28  
29 kinds of aminoglycosides antibiotics were dissolved in 0.01 M PBS for stock solution  
30  
31 with concentration of 1 mg mL<sup>-1</sup>. Tilmicosin was dissolved in DMF for stock solution.  
32  
33 Each analogue was diluted with 0.01 M HEPES into different concentrations (5, 10,  
34  
35 20, 50, 100, 200, and 500 µg L<sup>-1</sup>) for ic-ELISA.  
36  
37  
38  
39  
40

41 18 **Recovery test**

42  
43 Nata was fortified into negative milk, yoghurt, cheese, and juice for the recovery tests.  
44  
45 For milk and juice samples, 3 mL of methanol was added into 1 mL of samples to  
46  
47 allow the precipitation of protein under ultrasonic extraction for 30 min. The mixture  
48  
49 was centrifuged at 875 rcf for 5 min; the resulting supernatant was filtered through a  
50  
51 0.22 µm microporous membrane to obtain the pure liquid, which was diluted ten  
52  
53 times to the final concentrations (1, 2, and 5 µg L<sup>-1</sup>) for the ic-ELISA. As semisolid  
54  
55 samples, negative yoghurt and cheese were firstly homogenized and then spiked with  
56  
57  
58  
59  
60

1  
2  
3 1 Nata, following with the similar ultrasonic extraction process like milk and juice.  
4  
5 2 After extraction, 1 mL of pure water was added into the mixture and kept in 4°C for  
6  
7 3 1h, following with the centrifugation. After a microfiltration, the extraction was  
8  
9 4 diluted to the final concentrations (1, 2, and 5  $\mu\text{g L}^{-1}$ ) for the ic-ELISA.  
10  
11  
12 5

## 14 **Results and discussion**

### 17 **Antigen conjugation**

18  
19 8 To be immunogenic, small molecules such as Nata have to be covalently coupled with  
20  
21 9 a carrier protein, including BSA, KLH, and OVA<sup>34</sup>. BSA and KLH are usually used  
22  
23 10 for the conjugation of immunogens; OVA is often used for the conjugation of coating  
24  
25 11 antigens. Nata is a polyene macrolide, which contains four alkenes in an annular  
26  
27 12 structure. Nata is completely stable under the pH value of most food products; and the  
28  
29 13 solubility of Nata will increase under pH > 9 or pH < 3. In addition, it is relatively  
30  
31 14 stable under dry conditions and even can tolerate high temperatures for short time.  
32  
33 15 However, due to its annular structure, Nata is relatively sensitive to ultraviolet rays.  
34  
35 16 Hence, it is crucial to prevent Nata from light. To confirm successful conjugation, UV  
36  
37 17 absorbances recorded from 200 to 500 nm of Nata, BSA, OVA, and their conjugates  
38  
39 18 were measured, respectively. The maximum absorbance peak of BSA is at 278 nm  
40  
41 19 generated from its aromatic group and Nata has three obvious characteristic  
42  
43 20 absorbance peaks at 292, 305, and 320 nm, which generated by the structure of  
44  
45 21 annular four alkenes. Deservedly, the conjugates should possess the characteristic  
46  
47 22 absorbance peaks of Nata cause that the superfluous Nata has been removed through  
48  
49 23 dialysis. As shown in **Figure 1**, conjugates were successfully synthesized by the three  
50  
51 24 different methods. Generally speaking, the GA method is frequently applied for the  
52  
53 25 conjugation between aliphatic amino group and carrier protein and it is the more  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 effective compared with EDC and CDI method. The ratio of conjugation through  
4  
5 2 three different methods were 14, 2, and 2.2, respectively.  
6

7  
8 3 As shown in **Table 1**, each kind of antiserum was evaluated with three different  
9  
10 4 coating antigens (Nata-GA-OVA, Nata-EDC-OVA, and Nata-CDI-OVA). Apparently,  
11  
12 5 the titer of antiserum (GA) is the highest, which caused by the high coupling ratio  
13  
14 6 between Nata and BSA. Glutaraldehyde, a common homobifunctional  
15  
16 7 crossing-linking agent, has been widely used in chemical synthesis <sup>35</sup>. The amino  
17  
18 8 group of Nata was aliphatic, so it is proper to active Nata using glutaraldehyde and  
19  
20 9 result in the high conjugate ratio. Simultaneously, the inhibition of antiserum (GA)  
21  
22 10 was optimum when Nata-GA-OVA or Nata-EDC-OVA was used as the coating  
23  
24 11 antigen.  
25  
26  
27  
28  
29

### 30 **Optimization of ic-ELISA**

31  
32 14 The ionic strength, pH values, and organic solvent content of the assay buffer could  
33  
34 15 affect protein conformation and significantly influence the binding of antigen to  
35  
36 16 antibody <sup>36</sup>. As shown in **Figure 2 (A)** and **(B)**, comparing with using 0.01 M PBS,  
37  
38 17 ic-ELISA had a higher titer and lower IC<sub>50</sub> values using 0.01 M HEPES to dilute Nata.  
39  
40 18 Organic solvent was often used to assist the hydrophobic analytes to dissolve in  
41  
42 19 sample buffer, while high concentrations of organic solvent can negatively affect the  
43  
44 20 properties of mAb (e.g., mAb sensitivity) owing to the presence of background and  
45  
46 21 nonspecific binding. As shown in **Figure 2 (B)**, the concentration of methanol had  
47  
48 22 little effect on the maximum optical density (OD). With 20% methanol (v/v) in 0.01M  
49  
50 23 HEPES, the sensitivity was poor due to antibody deactivation. With 5% methanol (v/v)  
51  
52 24 in 0.01M HEPES used as assay buffer, the ic-ELISA had the highest OD and the  
53  
54 25 lowest IC<sub>50</sub> values. As shown in **Figure 2 (C)**, the OD was less than 1 when pH value  
55  
56  
57  
58  
59  
60

1  
2  
3 was 9.6, while the OD was higher and IC<sub>50</sub> was lower than others under pH 7.2, which  
4  
5 indicated that pH 7.2 was the most optimal one.  
6

7  
8 The standard sigmoidal inhibition curve of Nata under the optimized conditions  
9  
10 was shown in **Figure 2 (D)**. The IC<sub>50</sub> value and the quantitative detection range (IC<sub>20</sub>–  
11  
12 IC<sub>80</sub>) was 1.69 and 0.64–4.46 µg L<sup>-1</sup>, respectively. The limit of detection (LOD) of the  
13  
14 method was 0.59 µg L<sup>-1</sup>.  
15

### 16 17 18 **Cross-reactivity**

19  
20 As shown in **Table 2**, the seven analogues almost have no cross-reactivities with Nata,  
21  
22 which indicated that the mAb against Nata was specific.  
23  
24

### 25 26 27 **Recovery tests**

28  
29 For liquid samples (e.g., milk and juice) were diluted 4 times during the extraction  
30  
31 process, while the semisolid samples (e.g., yoghurt and cheese) were diluted 5 times.  
32  
33 The supernatant was diluted ten times to eliminate the matrix interferences. As shown  
34  
35 in **Table 3**, the average recoveries of Nata fortified in negative milk, juice, yoghurt,  
36  
37 and cheese was 103–121%, 103–121%, 84–114%, and 89–108%, respectively. The  
38  
39 results revealed that the mAb against Nata can be applied for the detection of Nata in  
40  
41 milk, juice, yoghurt, and cheese using ic-ELISA.  
42  
43  
44

### 45 46 47 **Conclusions**

48  
49 In this study, a highly sensitive and specific mAb against Nata was developed for the  
50  
51 first time and it can satisfy the Nata detection of European Union. Subsequently, a  
52  
53 simple and rapid ic-ELISA for Nata detection in milk, juice, yoghurt, and cheese, was  
54  
55 established, which can be employed for commercial ELISA kits and colloidal gold  
56  
57  
58  
59  
60

1  
2  
3 1 immunochromatographic strips.  
4  
5  
6

7  
8  
9 2

### 3 **Acknowledgements**

4 This work is financially supported by the Key Programs from MOST  
5 (2012BAK17B10, 2012BAD29B05, 2012BAK08B01), and grants from Natural  
6 Science Foundation of Jiangsu Province, MOF and MOE (BE2013613, BE2013611,  
7 BE2011626, 201310135).

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. L. Kallinteri, O. Kostoula and I. Savvaidis, *Food microbiology*, 2013, 36, 176-181.
2. M. Dervisoglu, O. Gul, O. Aydemir, F. Yazici and T. Kahyaoglu, *Food Additives & Contaminants: Part B*, 2014, 7, 1-7.
3. O. Hondrodinou, Y. Kourkoutas and E. Panagou, *Food microbiology*, 2011, 28, 621-627.
4. M. I. Tsiraki and I. N. Savvaidis, *Food chemistry*, 2014, 142, 416-422.
5. J. L. Koontz and J. E. Marcy, *Journal of agricultural and food chemistry*, 2003, 51, 7106-7110.
6. P. Fajardo, J. Martins, C. Fuciños, L. Pastrana, J. Teixeira and A. Vicente, *Journal of Food Engineering*, 2010, 101, 349-356.
7. C. M. Pintado, M. A. Ferreira and I. Sousa, *Food Control*, 2010, 21, 240-246.
8. G. P. Camilloto, N. de Fátima Ferreira Soares, A. C. dos Santos Pires and F. S. de Paula, *Packaging Technology and Science*, 2009, 22, 471-477.
9. R. A. Holley, *Applied and environmental microbiology*, 1981, 41, 422-429.
10. R. Paseiro-Cerrato, P. Otero-Pazos, A. Rodríguez-Bernaldo de Quirós, R. Sendón, I. Angulo and P. Paseiro-Losada, *Food Control*, 2013, 33, 262-267.
11. L. M. Repizo, L. D. Martinez, R. A. Olsina, S. Cerutti and J. Raba, *Analytical and bioanalytical chemistry*, 2012, 402, 965-973.
12. C. Guarino, F. Fuselli, A. L. Mantia and L. Longo, *Food chemistry*, 2011, 127, 1294-1299.
13. D. P. Roberts, M. J. Scotter, M. Godula, M. Dickinson and A. J. Charlton, *Analytical Methods*, 2011, 3, 937-943.

- 1  
2  
3  
4 14. M. Feng, Q. Yong, W. Wang, H. Kuang, L. Wang and C. Xu, *Food Agric. Immunol.*, 2013, 24,  
5  
6 481-487.  
7  
8  
9 3 15. I. Giovannacci, C. Guizard, M. Carlier, V. Duval, J. L. Martin and C. Demeulemester,  
10  
11 *International journal of food science & technology*, 2004, 39, 863-867.  
12  
13 5 16. J. Peng, S. Song, L. Xu, W. Ma, L. Liu, H. Kuang and C. Xu, *International journal of*  
14  
15 *environmental research and public health*, 2013, 10, 2897-2905.  
16  
17  
18 7 17. J. Peng, X. Meng, X. Deng, J. Zhu, H. Kuang and C. Xu, *Food Agric. Immunol.*, 2014, 25,  
19  
20 1-8.  
21  
22  
23 9 18. H. Kuang, C. Xing, C. Hao, L. Liu, L. Wang and C. Xu, *Sensors*, 2013, 13, 4214-4224.  
24  
25  
26 10 19. C. Xing, C. Hao, L. Liu, C. Xu and H. Kuang, *Food Agric. Immunol.*, 2014, 25, 432-442.  
27  
28  
29 11 20. N. Kong, L. Guo, D. Guan, L. Liu, H. Kuang and C. Xu, *Food Analytical Methods*, 2014, 1-8.  
30  
31  
32 12 21. H.-T. Zhang, J.-Q. Jiang, Z.-L. Wang, J.-J. Chen, S.-Y. Wang, H. Ding, X.-p. Li and Y. Li,  
33  
34 *Food Agric. Immunol.*, 2014, 25, 256-266.  
35  
36 14 22. M. J. Kim, J. Y. Shim, Y. T. Lee and H. S. Lee, *International journal of food science &*  
37  
38 *technology*, 2006, 41, 927-932.  
39  
40  
41 16 23. X. Chen, L. Xu, W. Ma, L. Liu, H. Kuang, C. Peng, L. Wang and C. Xu, *Immunological*  
42  
43 *investigations*, 2013, 42, 493-503.  
44  
45  
46 18 24. J. Guo, L. Liu, F. Xue, C. Xing, S. Song, H. Kuang and C. Xu, *Food Agric. Immunol.*, 2014,  
47  
48 1-11.  
49  
50  
51 20 25. J. K. Zhang, Y. H. Qi, J. X. Liu and J. P. Wang, *Food Agric. Immunol.*, 2013, 24, 419-431.  
52  
53  
54 21 26. N. Liu, S. Song, L. Lu, D. Nie, Z. Han, X. Yang, Z. Zhao, A. Wu and X. Zheng, *Food Agric.*  
55  
56 *Immunol.*, 2014, 25, 523-534.  
57  
58  
59  
60

- 1  
2  
3  
4 1 27. Y. Yin, L. Liu, S. Song, H. Kuang and C. Xu, *Food Agric. Immunol.*, 2014, 1-10.  
5  
6 2 28. S. Suryoprabowo, L. Liu, J. Peng, H. Kuang and C. Xu, *Food Analytical Methods*, 2014, 1-6.  
7  
8 3 29. X. Zhang, M. Feng, L. Liu, C. Xing, H. Kuang, C. Peng, L. Wang and C. Xu, *International*  
9  
10 4 *Journal of Food Science & Technology*, 2013, 48, 1269-1274.  
11  
12 5 30. J. Jiang, Z. Wang, H. Zhang, X. Zhang, X. Liu and S. Wang, *Journal of agricultural and food*  
13  
14 6 *chemistry*, 2011, 59, 9763-9769.  
15  
16 7 31. F. Sun, L. Liu, H. Kuang and C. Xu, *Food Agric. Immunol.*, 2013, 24, 79-86.  
17  
18 8 32. L. Wang, Y. Zhang, X. Gao, Z. Duan and S. Wang, *Journal of agricultural and food chemistry*,  
19  
20 9 2010, 58, 3265-3270.  
21  
22 10 33. L. Liu, H. Kuang, C. Peng, L. Wang and C. Xu, *Analytical Methods*, 2014, 6, 229-234.  
23  
24 11 34. Y. Zhang, S. Lu, W. Liu, C. Zhao and R. Xi, *Journal of agricultural and food chemistry*, 2007,  
25  
26 12 55, 211-218.  
27  
28 13 35. N. S. K. Gunda, M. Singh, L. Norman, K. Kaur and S. K. Mitra, *Applied Surface Science*,  
29  
30 14 2014, 305, 522-530.  
31  
32 15 36. Y. Cui, K. Liu, C. Xu, F. Liu, Q. X. Li, S. Liu and B. Wang, *Food chemistry*, 2014, 143,  
33  
34 16 293-299.  
35  
36 17  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46 18  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Captions:**  
4


5  
6 **Fig. 1** The UV-Vis absorption spectra of Nata-BSA (A) and Nata-OVA (B). The  
7  
8 concentrations of Nata-BSA (Nata-GA-BSA, Nata-EDC-BSA, and Nata-CDI-BSA)  
9  
10 and Nata-OVA (Nata-GA-OVA, Nata-EDC-OVA, and Nata-CDI-OVA) were both 0.5  
11  
12 mg mL<sup>-1</sup>.  
13

14  
15 **Fig. 2** Optimization of assay buffer for ic-ELISA: (A) Effect of methanol content in  
16  
17 PBS on ic-ELISA performance; (B) Effect of methanol content in HEPES on  
18  
19 ic-ELISA performance; (C) Effect of pH value of assay buffer on ic-ELISA  
20  
21 performance; (D) Standard curve of inhibition. Coating antigen: Nata-GA-OVA,  
22  
23 0.0625 µg mL<sup>-1</sup>; antibody: 1:64000; standards: 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20  
24  
25 µg L<sup>-1</sup>. Each point represents the mean of ±SD of three replicates.  
26  
27


28 **Table 1** Titer and inhibition of nine combinations of immunogens and coating  
29  
30 antigens.  
31

32 **Table 2** Cross-reactivity of the mAb  
33

34 **Table 3** Recovery test for Nata spiked in milk, juice, yoghurt, and cheese.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Fig. 1** The UV-Vis absorption spectra of Nata-BSA (A) and Nata-OVA (B). The concentrations of Nata-BSA (Nata-GA-BSA, Nata-EDC-BSA, and Nata-CDI-BSA) and Nata-OVA (Nata-GA-OVA, Nata-EDC-OVA, and Nata-CDI-OVA) were both  $0.5 \text{ mg mL}^{-1}$ .



**Fig. 2** Optimization of assay buffer for ic-ELISA: (A) Effect of methanol content in PBS on ic-ELISA performance; (B) Effect of methanol content in HEPES on ic-ELISA performance; (C) Effect of pH value of assay buffer on ic-ELISA performance; (D) Standard curve of inhibition. Coating antigen: Nata-GA-OVA,  $0.0625 \mu\text{g mL}^{-1}$ ; antibody: 1:64000; standards: 0.3125, 0.625, 1.25, 2.5, 5, 10, and  $20 \mu\text{g L}^{-1}$ . Each point represents the mean of  $\pm$ SD of three replicates.








**Table 1** Titer and inhibition of nine combinations of immunogens and coating antigens

coating antigen	antiserum(GA)		antiserum(EDC)		antiserum(CDI)	
	titer <sup>a</sup> inhibition <sup>b</sup>		titer inhibition		titer inhibition	
	( $\times 10^3$ ) (%)		( $\times 10^3$ ) (%)		( $\times 10^3$ ) (%)	
Nata-GA-OVA	9	45	6	41	<1	39
Nata-EDC-OVA	9	60	8	52	<1	23
Nata-CDI-OVA	<1	10	<1	15	6	10

<sup>a</sup>Titer is defined as dilution factor of antiserum in the absorbance at 450 nm under the coating concentration of  $0.1 \mu\text{g L}^{-1}$ .


<sup>b</sup>Inhibition ration was calculated as follow: inhibition (%) =  $[1 - (B / B_0)] \times 100$ .  $B_0$  was mean value of absorbance of wells without competitor;  $B$  was mean value of absorbance of wells in the presence of competitor ( $10 \mu\text{g L}^{-1}$ ).

1 **Table 2** Cross-reactivity of the mAb

Compound	Structure	IC <sub>50</sub> ( $\mu\text{g L}^{-1}$ )	Cross-reactivity (%)
Natamycin		1.69	100
Tylosin		>500	<0.1
Tilmicosin		>500	<0.1
Vancomycin		>500	<0.1
Gentamycin		>500	<0.1
Kanamycin		>500	<0.1
Streptomycin		>500	<0.1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Neomycin



>500

<0.1

1  
2  
3

1 **Table 3** Recovery test for Nata spiked in milk, juice, yoghurt, and cheese.

Matrix	Spike Nata ( $\mu\text{g L}^{-1}$ )	Mean $\pm$ SD ( $\mu\text{g L}^{-1}$ )	Intraassay		Mean $\pm$ SD ( $\mu\text{g L}^{-1}$ )	Interassay	
			Recovery (%)	CV (%)		Recovery (%)	CV (%)
Milk	1	1.20 $\pm$ 0.05	120.0 $\pm$ 5.0	4.17	0.94 $\pm$ 0.03	94.0 $\pm$ 3.0	3.19
	2	2.19 $\pm$ 0.15	109.5 $\pm$ 7.5	6.85	2.05 $\pm$ 0.03	102.5 $\pm$ 1.5	1.46
	5	5.13 $\pm$ 0.40	102.6 $\pm$ 8.0	7.80	4.92 $\pm$ 0.03	98.4 $\pm$ 0.6	0.61
Juice	1	1.21 $\pm$ 0.02	121.0 $\pm$ 2.0	1.65	1.09 $\pm$ 0.05	109.0 $\pm$ 5.0	4.59
	2	2.37 $\pm$ 0.03	118.5 $\pm$ 1.5	1.27	2.13 $\pm$ 0.03	106.5 $\pm$ 1.5	1.41
	5	5.05 $\pm$ 0.05	101.0 $\pm$ 1.0	0.99	4.95 $\pm$ 0.03	99.0 $\pm$ 0.6	0.61
Yoghurt	1	0.93 $\pm$ 0.04	93.0 $\pm$ 4.0	4.30	0.89 $\pm$ 0.03	89.0 $\pm$ 3.0	3.37
	2	2.27 $\pm$ 0.03	113.5 $\pm$ 1.5	1.32	1.85 $\pm$ 0.04	92.5 $\pm$ 2.0	2.16
	5	4.19 $\pm$ 0.02	83.8 $\pm$ 0.4	0.48	4.51 $\pm$ 0.04	90.2 $\pm$ 0.8	0.89
Cheese	1	0.90 $\pm$ 0.03	90.0 $\pm$ 3.0	5.17	0.88 $\pm$ 0.03	88.0 $\pm$ 3.0	3.82
	2	2.16 $\pm$ 0.04	108.0 $\pm$ 2.0	3.26	1.83 $\pm$ 0.03	91.5 $\pm$ 1.5	4.78
	5	4.43 $\pm$ 0.02	88.6 $\pm$ 0.4	4.62	4.64 $\pm$ 0.04	92.8 $\pm$ 0.8	2.96

2

3

4